Antimuscarinics have been the standard-of-care pharmacological approach for the noninvasive management of patients with a range of storage lower urinary tract symptoms (LUTS) for several

decades. However, despite these agents being effective in most patients, the adverse event profile often precludes long-term use.

In 2012, the FDA approved the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder syndrome. Treatment with this agent results in fewer, and better-tolerated adverse

events than treatment with antimuscarinics. However, some urologists remain sceptical about the efficacy of mirabegron.